TY - JOUR
T1 - Estimation of Prostatic Growth Using Serial Prostate-specific Antigen Measurements in Men with and without Prostate Disease
AU - Carter, H. Ballentine
AU - Morrell, Christopher H.
AU - Pearson, Jay D.
AU - Brant, Larry J.
AU - Plato, Constantine C.
AU - Jeffrey Metter, E.
AU - Chan, Daniel W.
AU - Fozard, James L.
AU - Walsh, Patrick C.
PY - 1992/6
Y1 - 1992/6
N2 - Prostate growth curves were estimated from serial prostate-specific antigen (PSA) measurements on frozen sera in three groups of men: (a) 16 men with no prostatic disease by urological history and examination; (b) 20 men with a histological diagnosis of benign prostatic hyperplasia (BPH) who had undergone simple prostatectomy; and (c) 18 men with a histological diagnosis of prostate cancer. The median number of repeated PSA measurements over an 8- to 26-yr period prior to histological diagnosis or exclusion of prostate disease was eight and 11 for noncancer and cancer subjects, respectively. Predicted rates of change in PSA (PSA velocity) were linear and curvilinear for control and BPH subjects, respectively. Subjects with cancer demonstrated both a linear and an exponential phase of PSA velocity. Based on time to double PSA, we estimated the epithelial doubling time for men without prostate disease to range from 54 ± 13 yr at age 40 to 84 ± 13 yr at age 70. For men with BPH, doubling times ranged from 2 ± 13 yr at age 40 to 17 ± 5 yr at age 85. Subjects with local/regional and advanced/metastatic cancer had similar PSA doubling times of 2.4 ± 0.6 yr and 1.8 ± 0.2 yr, respectively. These data are consistent with what is known about prostatic growth with age in men without prostate disease and BPH, and the kinetics of prostate cancer growth. Estimates of prostatic growth rate from changes in PSA may be useful clinically in management of men with prostate disease.
AB - Prostate growth curves were estimated from serial prostate-specific antigen (PSA) measurements on frozen sera in three groups of men: (a) 16 men with no prostatic disease by urological history and examination; (b) 20 men with a histological diagnosis of benign prostatic hyperplasia (BPH) who had undergone simple prostatectomy; and (c) 18 men with a histological diagnosis of prostate cancer. The median number of repeated PSA measurements over an 8- to 26-yr period prior to histological diagnosis or exclusion of prostate disease was eight and 11 for noncancer and cancer subjects, respectively. Predicted rates of change in PSA (PSA velocity) were linear and curvilinear for control and BPH subjects, respectively. Subjects with cancer demonstrated both a linear and an exponential phase of PSA velocity. Based on time to double PSA, we estimated the epithelial doubling time for men without prostate disease to range from 54 ± 13 yr at age 40 to 84 ± 13 yr at age 70. For men with BPH, doubling times ranged from 2 ± 13 yr at age 40 to 17 ± 5 yr at age 85. Subjects with local/regional and advanced/metastatic cancer had similar PSA doubling times of 2.4 ± 0.6 yr and 1.8 ± 0.2 yr, respectively. These data are consistent with what is known about prostatic growth with age in men without prostate disease and BPH, and the kinetics of prostate cancer growth. Estimates of prostatic growth rate from changes in PSA may be useful clinically in management of men with prostate disease.
UR - http://www.scopus.com/inward/record.url?scp=0026755373&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026755373&partnerID=8YFLogxK
M3 - Article
C2 - 1375867
AN - SCOPUS:0026755373
SN - 0008-5472
VL - 52
SP - 3323
EP - 3328
JO - Cancer Research
JF - Cancer Research
IS - 12
ER -